Follow Us:Respiratio 2018; 8 (1-2):74-82
UTICAJ GLIKOREGULACIJE NA PLUĆNE FUNKCIJE KOD OBOLJELIH OD CISTIČNE FIBROZE
THE INFLUENCE OF GLIKOREGULATION ON PULMONARY FUNCTIONS IN PATIENTS WITH CISTIC
OliveraLjuboja¹, GordanaBukaraRadujković², DraganaMalčić Zanić¹, VesnaMiljković¹
¹Univerzitetski klinički centar Republike Srpske, Banja Luka, Republika Srpska, Bosna i Hercegovina
²Univerzitet u Banjoj Luci, Medicinski fakultet, Banja Luka, Republika Srpska, Bosna i Hercegovina
Original research
Naučni članak
doi: 10.26601/rsp.aprs.18.10
Sažetak: Uvod: Produžavanje životnog vijeka u odraslu dob bolesnike sa cističnom fibrozom (CF) suočava sa novim terapijskim potrebama i komplikacijama bolesti, ne samo na plućima već i drugim organskim sistemima. Dijabetes melitus kod oboljelih od cistične fibroze (engl. Cystic fibrosis-related diabetes CFRD) je najčešća ekstrapulmonalna komplikacija.
Cilj rada: je bio utvrditi da li postoji korelacija između stepena oštećenja plućnih funkcija i nutritivnog statusa sa vrijednostima glikemije dobijenim kontinuiranim glukoznim monitoringom kod bolesnika sa CF u Republici Srpskoj.
Materijal i metode: kod 10 bolesnika sa cističnom fibrozom uzrasta od 7 do 37 godina je vršeno kontinuirano praćenje glukoze tokom sedmodnevnog nošenja uređaja iPro2® (Medtronic MiniMed). Dobijene vrijednosti su korelirane sa vrijednostima plućnih funkcija i stanja uhranjenosti bolesnika.
Rezultati: vrijednosti glikemije dobijene kontinuirnom glukoznim monitorningom su u direktnoj negativnoj korelaciji sa stepenom oštećenja plućnih funkcija i nutritivnim statusom kod ispitivanih bolesnika.
Zaključak: stepen poremećaja metabolizma glukoze je značajan prediktor oštećenja plućnih funkcija kod bolesnika sa cističnom fibrozom.
Ključne riječi: cistična fibroza, plućne funkcije, kontinuirani monitoring glukoze.
LITERATURA
|
1. Grasemann H, Ratjen F. Early lung disease in cystic fibrosis. Lancet Respir Med 2013;1(2):148–57. |
|
|
|
|
|
2. Andersen DH .Cystic fibrosis of the pancreas and its relation to celiac disease:a clinical and pathological study.Am J Dis Child.1938; 56(2):344-399. |
|
|
|
|
|
3. Simmonds NJ, Bush A. Diagnosing cystic fibrosis: what are we sweating about? Thorax. 2012; 67(7):571-3. |
|
|
|
|
|
4. Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W.Cystic fibrosis –related diabetes :current trends in prevalence, incidence, and mortality. Dibetes Care 2009; 32:1626-31. |
|
|
|
|
|
5. American Diabetes A. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012; 35 (1): S64-71. |
|
|
|
|
|
6. Moran A, Pillary K, Becker DJ, Acerini CL. International Society for P, Adolescent D, ISPAD clinical practice consensus guidelines 2014. Management of cystic fibrosis-related diabetes in children and adolescents. Pediatr Diabetes 2014; 15(20): 65-76. |
|
|
|
|
|
7. Brodsky J, Douugherty S, Makani R, Rubenstein RC, Kelly A. Elevation of 1-hour plasma glucose during oral glucose tolerance testing is associated with worse pulmonary function in cystic fibrosis. Diabetes Care 2011; 34(2):292-5. |
|
|
|
|
|
8. Chan CL, et al. Continuous glucose monitoring abnormalities in cystic fibrosis youth correlate with pulmonary function decline. J Cyst Fibrosis. 2018. |
|
|
|
|
|
9. de Onis M. WHO Child Growth Standards based on length/height, weight and age. Act Pediatric 2006; 95:76-85. |
|
|
|
|
|
10. Moran A, Brunzelli C, Cohen RC, Katz M, Marshall BC, Onady G. et al. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Associattion and clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care 2010; 33(12): 2697-708. |
|
|
|
|
|
11. OʹRiordan SM, Hindmarsh P, Hill NR, et al. Validation of continuous glucose monitoring in children and adolescents with cystic fibrosis: a prospective cohort study. Diabetes Care 2009; 32:1020-1022. |
|
|
|
|
|
12. Mehta G, Macek Jr M, Mehta A. Cystic fibrosis across Europe: EuroCareCF analysis of demographic data from 35 countries. J Cyst Fibros 2010;9(2):S5–S21. |
|
|
|
|
|
13. van der Doef HP, Kokke FT, van der Ent CK, Houwen RH. Intestinal obstruction syndromes in cystic fibrosis: meconium ileus, distal intestinal obstruction syndrome, and constipation. Curr Gastroenterol Rep. 2011; 13(3):265-70. |
|
|
|
|
|
14. Urquhart DS, Thia LP, Francis J, Prasad SA, Dawson C, Wallis C, Balfour-Lynn IM. Deaths in childhood from cystic fibrosis: 10-year analysis from two London specialist centres. Arch Dis Child. 2013; 98(2):123-7. |
|
|
|
|
|
15. Schluchter MD, Konstan MW, Drumm ML, Yankaskas JR, Knowles MR Classifying severity of cystic fibrosis lung disease using longitudinal pulmonary function data. Am J Respir Crit Care Med. 2006; 174(7):780-6. |
|
|
|
|
|
16. Florescu L, Paduraru DT, Mîndru DE, Temneanu OR, Petrariu FD, Matei MC. Epidemiological evaluation regarding the role of cystic fibrosis as a risk factor for child malnutrition. Rev Med Chir Soc Med Nat Iasi. 2014; 118(2):450-6. |
|
|
|
|
|
17. Walkowiak J, Lisowska A, Blaszczyński M. The changing face of the exocrine pancreas in cystic fibrosis: pancreatic sufficiency, pancreatitis and genotype. Eur J Gastroenterol Hepatol. 2008; 20(3):157-60. |
|
|
|
|
|
18. Littlewood JM, Wolfe SP, Conway SP. Diagnosis and treatment of intestinal malabsorption in cystic fibrosis. Pediatr Pulmonol. 2006;41(1):35-49. |
|
|
|
|
|
19. Govan JR, Brown AR, Jones AM. Evolving epidemiology of Pseudomonas aeruginosa and the Burkholderia cepacia complex in cystic fibrosis lung infection. Future Microbiol. 2007; 2(2):153-64 |
|
|
|
|
|
20. McPhail GL, Acton JD, Fenchel MC, Amin RS, Seid M. Improvements in lung function outcomes in children with cystic fibrosis are associated with better nutrition, fewer chronic pseudomonas aeruginosa infections, and dornase alfa use. J Pediatr. 2008; 153(6):752-7. |
|
|
|
|
|
21. Ntimbane T, Mailhot G, Spahis S, et al. CFTR silencing in pancreatic β-cells reveals a functional impact on glucose-stimulated insulin secretion and oxidative stress response. Am J Physiol Endocrinol Metab. 2016;310(3):E200-212. |
|
|
|
|
|
22. Bilodeau C, Bardou O, Maillé É, Berthiaume Y, Brochiero E. Deleterious impact of hyperglycemia on cystic fibrosis airway ion transport and epithelial repair. J Cyst Fibros. 2016;15(1):43-51. |
|
|
|
|
|
23. Kelly A, Moran A. Update on cytic fibrosis-related diabetes. J Cyst Fibrosis 2013; 12(4):318-31. |
|
|
|
|
|
24. Hirsch IB. Glycemic variability and diabetes complications:does it matter? Of course it does! Diabetes Care 2015; 38 (8):1610-4. |
|
|
|
|
|
25. Sanders DB, Li Z, Laxova A, Rock MJ, Levy H, Collins J, et al. Risk factors for the progression of cystic fibrosis lung disease throughout childhood. Ann Am Thorac Soc 2014;11(1):63–72. [23] |
|
Olivera Ljuboja
Klinika za dječije bolesti.
Univerzitetski Klinički centar Republike Srpske
Mob. 065 527 098
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.